Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0I2GS
|
|||
| Drug Name |
Contezolid
|
|||
| Synonyms |
MRX-I; UNII-B669M62ELP; B669M62ELP; CHEMBL3287379; 1112968-42-9; 4(1H)-Pyridinone, 2,3-dihydro-1-(2,3,6-trifluoro-4-((5S)-5-((3-isoxazolylamino)methyl)-2-oxo-3-oxazolidinyl)phenyl)-; 4(1H)-Pyridinone, 2,3-dihydro-1-[2,3,6-trifluoro-4-[(5S)-5-[(3-isoxazolylamino)methyl]-2-oxo-3-oxazolidinyl]phenyl]-; Contezolid [USAN]; SCHEMBL5945221; BDBM50017203; DB12796
Click to Show/Hide
|
|||
| Indication | MRSA infection [ICD-11: 1D01.0Y; ICD-10: A49.02; ICD-9: 41.12] | Phase 2 | [1] | |
| Skin infection [ICD-11: 1F28-1G0Z; ICD-10: L00-L99; ICD-9: 680-709] | Phase 2 | [2] | ||
| Company |
MicuRx Pharmaceuticals Hayward, CA
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H15F3N4O4
|
|||
| Canonical SMILES |
C1CN(C=CC1=O)C2=C(C=C(C(=C2F)F)N3CC(OC3=O)CNC4=NOC=C4)F
|
|||
| InChI |
1S/C18H15F3N4O4/c19-12-7-13(15(20)16(21)17(12)24-4-1-10(26)2-5-24)25-9-11(29-18(25)27)8-22-14-3-6-28-23-14/h1,3-4,6-7,11H,2,5,8-9H2,(H,22,23)/t11-/m0/s1
|
|||
| InChIKey |
SULYVXZZUMRQAX-NSHDSACASA-N
|
|||
| CAS Number |
CAS 1112968-42-9
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Protein synthesis (hPRO synth) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | MICURX PHARMACEUTICALS COMPLETES PHASE 1 TRIAL FOR MRX-I, A NEXT-GENERATION ANTIBIOTIC. Micurx pharmaceuticals. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.